Stereotactic ablative body radiation (SABR)

RADIATION4 trials

Conditions

Locally AdvancedLocally Advanced Pancreatic AdenocarcinomaLung CancerOligometastatic Renal Cell CarcinomaOligoprogressive Renal Cell CarcinomaPancreas Cancer

Phase 1

Five Fraction SABR Dose Escalation for Early Stage Squamous Cell Carcinoma of the Lung

TerminatedNCT03321747

Indiana UniversityLung Cancer

Start: 2017-10-20End: 2020-07-09Updated: 2022-07-26

Phase 2

SAbR For Oligo-Progressive Renal Cell Cancer.

CompletedNCT03696277

University of Texas Southwestern Medical CenterOligoprogressive Renal Cell Carcinoma

Start: 2018-10-01End: 2024-01-23Updated: 2024-07-17

Unknown Phase

SAbR For Oligometastatic Renal Cell Carcinoma

CompletedNCT02956798

University of Texas Southwestern Medical CenterOligometastatic Renal Cell Carcinoma

Start: 2018-07-19End: 2024-01-24Updated: 2026-08-31

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

RecruitingNCT05679674

Baptist Health South FloridaLocally Advanced, Locally Advanced Pancreatic Adenocarcinoma, Pancreas Cancer

Start: 2023-09-21End: 2027-06-30Target: 48Updated: 2026-01-12

Related Papers

Phase I Trial of Dose-Escalated Five-Fraction Stereotactic Ablative Radiotherapy for Early-Stage Lung Squamous Cell Carcinoma.

2021-11-01

Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.

Journal of Clinical Oncology2021-05-202 citations

Phase II trial of stereotactic ablative radiation (SAbR) for oligometastatic kidney cancer.

Journal of Clinical Oncology2021-02-208 citations